Aug. 16 at 4:45 AM
$XLO with a risk of delisting on the horizon, a pipeline update soon is needed… however i think there’s zero chance they do another offering or any more dilution until they are no longer at risk of delisting. Their cash runway is set to carry them until Q3 of 2026.
Fraziers warrants are limited as they cannot own more than 9.99% of
$XLO and they’re priced at
$1.50, meaning they won’t exercise on anything under that, secondly they can’t just dump all of their warrants at once.
$XLO has strategically positioned themselves financially for immense success. If you’ve been here a while, you know phase 1 of vilastobart caused a 22% jump in price before the offering, the science is there. The word “breakthrough” isn’t tossed around lightly in the medical field, however phase 1 was so promising that was being said. Phase 2 results will change lives
It is a matter of time before we are back to the
$1.00 range, and depending on the catalyst that gets it there, i don’t think it stops at
$1.00
